Ipamorelin + Tesamorelin Blend
GHRP + GHRH Dual-Axis Blend
Co-formulated ipamorelin (GHRP, ghrelin-receptor agonist) with tesamorelin (stabilized GHRH). Two ipamorelin-dose variants over constant 10 mg tesamorelin.
Blends & Stacks
Category
From $116.99
Price
Research
Grade
Price
From $116.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Reconstitute the blend in 1mL bacteriostatic water for a working concentration of 10mg/mL tesamorelin + 3mg/mL ipamorelin. Administer 200μL once daily subcutaneously — delivering the 2mg tesamorelin clinical reference dose plus 600μg ipamorelin. Evening administration aligns with the endogenous overnight GH pulse and the pivotal-trial dosing convention.
This blend answers a specific research question in growth-peptide pharmacology: can the synergistic amplification of a GHRH analog paired with a ghrelin-receptor agonist replicate body-composition endpoints from the tesamorelin pivotal trials while adding the somatotrope-responsive pulse signal that comes from GHRP engagement? The mechanism underlying the hypothesis is that GHRH and GHRP engage different signalling cascades in the pituitary somatotrope — GHRH through cAMP via GHRH-R, GHRP through intracellular calcium via GHS-R1a — and convergent activation produces a larger GH pulse than either component alone.
Ingredient Ratio
| Component A | Ipamorelin |
|---|---|
| Component B | Tesamorelin |
Available Sizes
Specifications
| Product | Ipamorelin + Tesamorelin Blend |
|---|---|
| Category | Blends & Stacks |
| Format | Lyophilized powder |
| Price | From $116.99 |
Mechanism Pair Outcomes
10mg tesamorelin + 3mg ipamorelin — GHRH-dominant ratio
Tesamorelin provides the FDA-approved visceral-fat reduction backbone
Ipamorelin adds GHS-R1a pulse signal without prolactin/cortisol spillover
5-day clinical-cadence research window per vial
Synergistic GH pulse from parallel cAMP and Ca²⁺ pathway engagement
Co-lyophilised with batch COA on both components
Dosing Guide
Reconstitute the blend in 1mL bacteriostatic water for a working concentration of 10mg/mL tesamorelin + 3mg/mL ipamorelin. Administer 200μL once daily subcutaneously — delivering the 2mg tesamorelin clinical reference dose plus 600μg ipamorelin. Evening administration aligns with the endogenous overnight GH pulse and the pivotal-trial dosing convention.
Ipamorelin + Tesamorelin Blend — FAQs
Also Explore: Blends & Stacks
View All
GLOW Blend 50mg
GLOW is a community-origin triple blend — GHK-Cu (copper tripeptide) + BPC-157 + TB-500 — assembled to combine Pickart's dermal collagen pharmacology with the orthogonal BPC/TB repair duo for aesthetic/skin research in one vial.
KLOW Blend 80mg
KLOW adds KPV (the α-MSH fragment tripeptide lysine-proline-valine) to the GLOW triple stack, giving a four-compound gut/skin research blend that combines anti-inflammatory melanocortin signalling with the three-axis repair logic of GHK-Cu/BPC/TB.
Cagri-Sema Blend 10mg
The 5mg Cagrilintide + 10mg Semaglutide co-formulated blend — a fixed-ratio research-format version of Novo Nordisk's CagriSema development program (REDEFINE-1 and REDEFINE-2 phase 3 trials), pairing long-acting amylin analog with GLP-1 agonism.
